Neuronal Trans-Differentiation in Prostate Cancer Cells

Prostate

Volumn 76, Issue 14, 2016, Pages 1312-1325

  Farach, Andrew ^a   Ding, Yi ^b   Lee, MinJae ^c   Creighton, Chad ^a   Delk, Nikki A ^d   Ittmann, Michael ^a   Miles, Brian ^e   Rowley, David ^a   Farach Carson, Mary C ^a,d   Ayala, Gustavo E ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d RICE UNIVERSITY   (United States)

^e HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

nerves; neuroendocrine; neuronal trans differentiation; neurons; prostate cancer; resistance phenotype; small cell

Indexed keywords

ANDROGEN RECEPTOR; APOPTOSIS STIMULATING OF P53 PROTEIN 2; BETA TUBULIN; BETA TUBULIN III; CELL PROTEIN; CONTACTIN ASSOCIATED PROTEIN 1; CYCLIC AMP; KI 67 ANTIGEN; NERVE GROWTH FACTOR; NEUROFILAMENT M PROTEIN; NEURON SPECIFIC ENOLASE; NEURON SPECIFIC NUCLEAR PROTEIN; PROSTATE SPECIFIC ANTIGEN; SEMAPHORIN; SEMAPHORIN 4F; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CELLULAR DISTRIBUTION; COMPUTER MODEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE ONTOLOGY; GENETIC ASSOCIATION; GENETIC DATABASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOLECULAR DYNAMICS; NERVE CELL DIFFERENTIATION; NEURONAL TRANSDIFFERENTIATION; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; UPREGULATION; VALIDATION PROCESS;

EID: 84982091040     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23221     Document Type: Article

References (42)

1. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997; 79(2):235–246.
2. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294(2):238–244.
3. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002; 360(9327):103–106.
4. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337(5):295–300.
5. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004; 292(7):821–827.
6. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341(24):1781–1788.
7. Bracarda S, Logothetis C, Sternberg CN, Oudard S. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. BJU Int 2011; 107(Suppl 2):13–20.
8. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004; 45(5):586–592; discussion 92.
9. Rau KM, Kang HY, Cha TL, Miller SA, Hung MC. The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr Relat Cancer 2005; 12(3):511–532.
10. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349(3):215–224.
11. Evangelou AI, Winter SF, Huss WJ, Bok RA, Greenberg NM. Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype. J Cell Biochem 2004; 91(4):671–683.
12. Zhang C, Soori M, Miles FL, Sikes RA, Carson DD, Chung LW, Farach-Carson MC. Paracrine factors produced by bone marrow stromal cells induce apoptosis and neuroendocrine differentiation in prostate cancer cells. Prostate 2011; 71(2):157–167.
13. Delk NA, Farach-Carson MC. Interleukin-6: A bone marrow stromal cell paracrine signal that induces neuroendocrine differentiation and modulates autophagy in bone metastatic PCa cells. Autophagy 2012; 8(4). Epub 2012/03/24. PubMed PMID: 22441019.
14. Tang Y, Wang L, Goloubeva O, Khan MA, Lee D, Hussain A. The relationship of neuroendocrine carcinomas to anti-tumor therapies in TRAMP mice. Prostate 2009; 69(16):1763–1773.
15. Huss WJ, Gray DR, Tavakoli K, Marmillion ME, Durham LE, Johnson MA, Greenberg NM, Smith GJ. Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia 2007; 9(11):938–950.
16. Ayala GE, Dai H, Ittmann M, Li R, Powell M, Frolov A, Wheeler TM, Thompson TC, Rowley D. Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res 2004; 64(17):6082–6090.
17. Ayala GE, Dai H, Powell M, Li R, Ding Y, Wheeler TM, Shine D, Kadmon D, Thompson T, Miles BJ, Ittmann MM, Rowley D. Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res 2008; 14(23):7593–7603.
18. Tosh D, Slack JM. How cells change their phenotype. Nat Rev Mol Cell Biol 2002; 3(3):187–194.
19. Jarriault S, Schwab Y, Greenwald I. A Caenorhabditis elegans model for epithelial-neuronal transdifferentiation. Proc Natl Acad Sci USA 2008; 105(10):3790–3795.
20. Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L, Ha MJ, Tsokos M, Sheahan MD, Nguyen P, Niklinski WT, Myers CE, Trepel JB. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci USA 1994; 91(12):5330–5334.
21. Zhang B, Kirov S, Snoddy J. WebGestalt: An integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 2005; 33(Web Server issue):W741–W748.
22. Kloukina-Pantazidou I, Chrysanthou-Piterou M, Havaki S, Issidorides MR. Chromogranin A and vesicular monoamine transporter 2 immunolocalization in protein bodies of human locus coeruleus neurons. Ultrastruct Pathol 2013; 37(2):102–109.
23. Bauer R, Ischia R, Marksteiner J, Kapeller I, Fischer-Colbrie R. Localization of neuroendocrine secretory protein 55 messenger RNA in the rat brain. Neuroscience 1999; 91(2):685–694.
24. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43(4):1809–1818.
25. Burchardt T, Burchardt M, Chen MW, Cao Y, de la Taille A, Shabsigh A, Hayek O, Dorai T, Buttyan R. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 1999; 162(5):1800–1805.
26. Jimenez N, Hernandez-Cruz A. Modifications of intracellular Ca2+ signalling during nerve growth factor-induced neuronal differentiation of rat adrenal chromaffin cells. Eur J Neurosci 2001; 13(8):1487–1500.
27. Shen R, Dorai T, Szaboles M, Katz AE, Olsson CA, Buttyan R. Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium. Urol Oncol 1997; 3(2):67–75.
28. Yuan S, Rosenberg L, Paraskevas S, Agapitos D, Duguid WP. Transdifferentiation of human islets to pancreatic ductal cells in collagen matrix culture. Differentiation 1996; 61(1):67–75.
29. Deeble PD, Murphy DJ, Parsons SJ, Cox ME. Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 2001; 21(24):8471–8482.
30. Palmer J, Ernst M, Hammacher A, Hertzog PJ. Constitutive activation of gp130 leads to neuroendocrine differentiation in vitro and in vivo. Prostate 2005; 62(3):282–289.
31. Yang X, Chen MW, Terry S, Vacherot F, Chopin DK, Bemis DL, Kitajewski J, Benson MC, Guo Y, Buttyan R. A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells. Cancer Res 2005; 65(12):5263–5271.
32. Sainz RM, Mayo JC, Tan DX, Leon J, Manchester L, Reiter RJ. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 2005; 63(1):29–43.
33. Pancrazio JJ, Viglione MP, Tabbara IA, Kim YI. Voltage-dependent ion channels in small-cell lung cancer cells. Cancer Res 1989; 49(21):5901–5906.
34. Johansson S, Rydqvist B, Swerup C, Heilbronn E, Arhem P. Action potentials of cultured human oat cells: Whole-cell measurements with the patch-clamp technique. Acta Physiol Scand 1989; 135(4):573–578.
35. Blandino JK, Viglione MP, Bradley WA, Oie HK, Kim YI. Voltage-dependent sodium channels in human small-cell lung cancer cells: Role in action potentials and inhibition by Lambert-Eaton syndrome IgG. J Membr Biol 1995; 143(2):153–163.
36. McCann FV, Pettengill OS, Cole JJ, Russell JA, Sorenson GD. Calcium spike electrogenesis and other electrical activity in continuously cultured small cell carcinoma of the lung. Science 1981; 212(4499):1155–1157.
37. Pinto JE, Viglione PN, Rothlin RP, Gomez C. Decrease of extracellular pH associated with the secretion of catecholamines induced by barium in perfused bovine adrenal medulla. Gen Pharmacol 1993; 24(2):503–508.
38. Fiske JL, Fomin VP, Brown ML, Duncan RL, Sikes RA. Voltage-sensitive ion channels and cancer. Cancer Metastasis Rev 2006; 25(3):493–500.
39. Benatar M, Blaes F, Johnston I, Wilson K, Vincent A, Beeson D, Lang B. Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line. J Neuroimmunol 2001; 113(1):153–162.
40. Dai H, Li R, Wheeler T, de Vivar AD, Frolov A, Tahir S, Agoulnik I, Thompson T, Rowley D, Ayala G. Pim-2 upregulation: Biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate 2005; 65(3):276–286.
41. Ayala GE, Dai H, Tahir SA, Li R, Timme T, Ittmann M, Frolov A, Wheeler TM, Rowley D, Thompson TC. Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Res 2006; 66(10):5159–5164.
42. Silva J, Pinto R, Carvallho T, Coelho A, Avelino A, Dinis P, Cruz F. Mechanisms of prostate atrophy after glandular botulinum neurotoxin type a injection: An experimental study in the rat. Eur Urol 2009; 56(1):134–140.